Event reported in a literature article: journal of pediatric hematology/oncology 2014;00:000-000.Accepted for publication october 3, 2014."safety and outcomes of extracorporeal photopheresis with the therakos cellex system for graft-versus-host-disease in pediatric patients." (b)(6) year-old boy, one of four patients (all four with liver involvement) in a retrospective review of twelve pediatric patients that failed to respond to the treatment and died of mucormycosis, evolved into mild chronic gvhd (skin).Hsct indication: fa, fanconi anemia donor: (b)(6), matched unrelated donor (b)(6).Stem cell: bm, bone marrow.Onset of gvhd (wk): 8.Gvhd treatment (pre-ecp): csa (cyclosporine), tacr (tacrolimus), mmf (mycophenolate mofetil), mp (methylprednisolone), sirolimus interval between onset of gvhd and ecp (wk): 13.Gvhd type: acute (biopsy proven).Affected organs (stage in agvhd, score in cgvhd): skin (2) degree of gvhd: grade 1 acute gvhd.Improvement: acute: grade 1 to 0.Ecp procedures: 6.Gvhd treatment during ecp: sirolimus.Beginning of improvement (if any) (number of procedures): 4.Survival: expired.Current status: died of mucormycosis, evolved into mild chronic gvhd (skin).The date of death was not reported.
|
No lot number was reported; therefore, no batch record review was performed.There were no trends detected for complaint categories, death or multi-organ failure.(b)(6)year old male with grade 1 acute gvhd of fanconi anemia died of mucormycosis; evolved into mild chronic gvhd.Patient only had 6 ecp treatments.This case is serious and not related to ecp therapy.Therakos is reporting this out of abundance of caution.Kit unique identifier (udi)#: (b)(4).
|